Top 5 Papers
#1
Source: Nature Communications | Authors: Choo J, Zhao JJ, Lau MC, Raimondi A, et al. | Published: April 25, 2026
Score: 9/20 — Base 6 (Nature Communications) + Phase II trial data (+2) + Biomarker-guided/precision (+1)
Integrated spatial, transcriptomic, and immune profiling of longitudinal samples from the MAYA trial (NCT03832621) in MGMT-silenced MSS mCRC. Post-temozolomide increases in tumor mutational burden associated with improved PFS. Spatial profiling showed clinical benefit was greatest in permissive tumor microenvironments: responders had enrichment of cytotoxic T cells across tumor and stromal compartments, while non-responders displayed fibroblast-T cell proximity barriers to immune-mediated clearance. Longitudinal peripheral immune profiling revealed that early TIGIT and PD-1 upregulation after TMZ predicted resistance. These findings show both mutational evolution and spatial immune architecture contribute to immune sensitization in MSS CRC.
Post angle: First spatial immune atlas of the MAYA trial — now we know WHY some MSS CRC patients respond to IO and others don't. Fibroblast barriers are the next therapeutic target. #CRC #MSS #ImmunoProfiling #GIOnc #PrecisionMedicine
#2
Source: Clinical Epigenetics | Authors: Long F, Xu Y, Wu K, Fu X, et al. | Published: April 25, 2026
Score: 6/20 — Base 5 (Other journal) + Biomarker-guided/precision (+1)
A 5-gene blood-based methylation panel (ELMO1, FGF12, NPY, SEPTIN9, ZNF671) was developed for gastric cancer screening using Random Forest modeling. In a training cohort of 605 subjects, the model achieved AUC 0.9585, sensitivity 81.85%, and specificity 92.49%. In an independent validation cohort of 152 subjects, AUC was 0.8868 with 82.19% sensitivity and 81.01% specificity. The model detected across all pathological stages with AUCs ranging from 0.82 (stage 0-IB) to 0.94 (stage IV), demonstrating potential for early-stage detection through a minimally invasive peripheral blood test.
Post angle: A simple blood test with AUC 0.96 for gastric cancer screening? This 5-gene methylation panel could replace gastroscopy for population screening. Validation needed at scale. #GastricCancer #LiquidBiopsy #EarlyDetection #GIOnc
#3
Source: Cellular and Molecular Life Sciences | Authors: Wang Y, Xue S, Xu H, Ma J, et al. | Published: April 25, 2026
Score: 6/20 — Base 5 (Other journal) + Biomarker-guided/precision (+1)
This study identified the bile acid tauroursodeoxycholic acid (TUDCA) as a promoter of chemoresistance in pancreatic ductal adenocarcinoma through MAPK signaling pathway activation. TUDCA levels predicted survival outcomes in PDAC patients, establishing it as both a mechanistic driver of gemcitabine resistance and a potential prognostic biomarker. The findings open new avenues for targeting bile acid metabolism to overcome chemotherapy resistance in PDAC, a cancer with notoriously poor treatment responses.
Post angle: Your bile acids might be sabotaging your chemo. TUDCA promotes gemcitabine resistance in PDAC via MAPK — a druggable axis and new prognostic biomarker. #PDAC #Chemoresistance #BileAcids #GIOnc #PrecisionMedicine
#4
Source: Scientific Reports | Authors: Yokoyama S, Noguchi H, Hamada T, Matsuo K, et al. | Published: April 25, 2026
Score: 6/20 — Base 5 (Other journal) + Biomarker-guided/precision (+1)
Using high-resolution bisulfite amplicon sequencing, researchers identified AQP1 promoter methylation haplotypes as a prognostic biomarker in cholangiocarcinoma. A t-SNE-based classification of methylation signatures identified two subgroups with distinct overall survival. Multivariate Firth's penalized Cox regression confirmed independent prognostic significance (HR 0.322, p=0.001). Notably, similar haplotype alterations were found in non-neoplastic and neoplastic tissues, consistent with an epigenetic field effect — suggesting the biomarker could potentially be detected in less-invasive tissue samples adjacent to the tumor.
Post angle: HR 0.32 — AQP1 methylation is a powerful independent prognostic marker in cholangiocarcinoma with evidence of an epigenetic field effect. Could enable less invasive risk stratification. #CCA #Cholangiocarcinoma #Epigenetics #GIOnc
#5
Source: Journal of Nanobiotechnology | Authors: Chen C, Song S, Wu W, Yu N, et al. | Published: April 26, 2026
Score: 5/20 — Base 5 (Other journal)
A thermosensitive nanogel (Cu2+/DC_AC50@PNA) co-loaded with copper ions and the ATOX1 inhibitor DC_AC50 was developed to overcome TACE refractoriness in HCC. Clinical analysis showed TACE-refractory patients had elevated serum copper and ATOX1/ATP7B expression. In VX2 orthotopic liver tumor models, the nanoembolization system markedly suppressed tumor growth, increased necrosis, reduced metastasis, and prolonged survival vs conventional TACE. Mechanistically, it disrupted copper transport, activated cuproptosis, inhibited HIF-1a/VEGF angiogenesis, and enhanced CD8+ T-cell infiltration.
Post angle: When TACE stops working, copper metabolism may be the culprit. This cuproptosis-inducing nanogel reverses TACE refractoriness in HCC — fascinating translational science. #HCC #TACE #Cuproptosis #LiverCancer #GIOnc
Additional Papers of Interest
-
Cancer Gene Therapy — Intranasal vaccine targeting mutant p53 (R270H) with nanoemulsion adjuvant decreased tumor size and prolonged survival in murine CRC model via Th1/Th17 and anti-p53 IgG responses
-
Abdominal Radiology — Normalized iodine concentration (nDIa) from dual-layer spectral CT achieves AUC 0.86 for preoperative PNI prediction in PDAC, outperforming conventional CT (AUC 0.68)
-
Clinical & Translational Oncology — Review of IL-1a as prognostic biomarker (HR 1.99) and therapeutic target in PDAC; IL-1a blockers (anakinra, canakinumab) show DCR up to 62% in combination trials
-
Langenbeck's Archives of Surgery — Pooled intraoperative GVC incidence 16.3% in pancreatic surgery; associated with DGE (17.3%), major complications (13.5%), and 4.3% 90-day mortality
-
Journal of Medical Economics — Atezo+bev yields 0.87 additional QALYs vs lenvatinib with ICER of ~0.91x GDP/capita, supporting cost-effectiveness in Malaysian healthcare system
Back to all digests